In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
BUSINESS
Eisai Sees Global Sales of Leqembi Surging to 56.5 Billion Yen in FY2024
Eisai expects global sales of its Alzheimer’s disease (AD) drug Leqembi (lecanemab) to hit 56.5 billion yen in FY2024 through March 2025, CEO Haruo Naito said on May 15. By region, the Japanese drug major foresees Leqembi reeling in 43.5…
To read the full story
Related Article
- Eisai Aims to Turn Leqembi to Black in FY2026 with EU Approval as Tailwind: CEO
May 16, 2025
- Eisai Eyes Up to 280 Billion Yen Sales for Leqembi in FY2027: CEO
March 26, 2025
- Eisai Cuts Leqembi Sales Target as It Sees “Some Delays” in US Uptake
November 11, 2024
- Leqembi Gathers Pace with Sales Up 2.7-Fold in January-March: Eisai
April 25, 2024
- Eisai CEO Confident in Leqembi Uptake, Says 90% of US Hospital Targets to Adopt Med by March-End
March 8, 2024
- 2,000 Patients Receiving Leqembi in US, 4 Times the Number on Wait List: Eisai
February 7, 2024
- Eisai’s H1 Operating Profit Spikes on Lenvima Growth, Divestment Gain
November 8, 2023
- Broader Use of Blood Biomarkers Key to Maximizing Leqembi’s Value: Eisai Exec
October 18, 2023
- Eisai Sees Positive Shift in US Market for Leqembi after Full Approval: Exec
August 3, 2023
BUSINESS
- Fuji, J&J Reach Agreement on Simponi Biosimilar for 2026 Debut
November 5, 2025
- Takeda Mulls Boost in Imports amid Kenketu Glovenin-I Suspension
November 5, 2025
- Takeda Halts Shipments of Kenketu Glovenin-I to Review Narita Plant Process
November 5, 2025
- Maruho, Nielsen Ink Licensing Deal for Common Warts Therapy in Asia
November 5, 2025
- MHLW Veteran Katsufumi Jo Joins BCG as Senior Advisor
November 5, 2025
Japan’s Ministry of Health, Labor and Welfare (MHLW) proposed a full review of the so-called “G1/G2” rule — a framework…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…